Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

被引:3301
|
作者
Tong, Steven Y. C. [1 ]
Davis, Joshua S. [1 ]
Eichenberger, Emily [2 ]
Holland, Thomas L. [2 ]
Fowler, Vance G., Jr. [2 ,3 ]
机构
[1] Menzies Sch Hlth Res, Global & Trop Hlth, Darwin, NT, Australia
[2] Duke Univ, Med Ctr, Dept Med, Div Infect Dis, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA
基金
美国国家卫生研究院;
关键词
SMALL-COLONY VARIANTS; PANTON-VALENTINE LEUKOCIDIN; PROSTHETIC VALVE ENDOCARDITIS; SKIN-STRUCTURE INFECTIONS; SPINAL EPIDURAL ABSCESS; TOXIC-SHOCK-SYNDROME; SOFT-TISSUE INFECTIONS; BLOOD-STREAM INFECTIONS; ACUTE BACTERIAL SKIN; COMMUNITY-ACQUIRED PNEUMONIA;
D O I
10.1128/CMR.00134-14
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Staphylococcus aureus is a major human pathogen that causes a wide range of clinical infections. It is a leading cause of bacteremia and infective endocarditis as well as osteoarticular, skin and soft tissue, pleuropulmonary, and device-related infections. This review comprehensively covers the epidemiology, pathophysiology, clinical manifestations, and management of each of these clinical entities. The past 2 decades have witnessed two clear shifts in the epidemiology of S. aureus infections: first, a growing number of health care-associated infections, particularly seen in infective endocarditis and prosthetic device infections, and second, an epidemic of community-associated skin and soft tissue infections driven by strains with certain virulence factors and resistance to beta-lactam antibiotics. In reviewing the literature to support management strategies for these clinical manifestations, we also highlight the paucity of high-quality evidence for many key clinical questions.
引用
收藏
页码:603 / 661
页数:59
相关论文
共 50 条
  • [31] Epidemiology and Clinical Impact of Glycopeptide Resistance in Staphylococcus aureus
    C. Ruef
    Infection, 2004, 32 : 315 - 327
  • [32] Nosocomial infections caused by multiresistant bacteria. Clinical management of infections with multiresistant Staphylococcus aureus (MRSA)Klinisches Management am Beispiel des multiresistenten Staphylococcus aureus (MRSA)
    H.-J. Knopf
    Der Urologe A, 1997, 36 : 248 - 254
  • [33] Clinical management of Staphylococcus aureus bacteraemia
    Thwaites, Guy E.
    Edgeworth, Jonathan D.
    Gkrania-Klotsas, Effrossyni
    Kirby, Andrew
    Tilley, Robert
    Toeroek, M. Estee
    Walker, Sarah
    Wertheim, Heiman F. L.
    Wilson, Peter
    Llewelyn, Martin J.
    LANCET INFECTIOUS DISEASES, 2011, 11 (03): : 208 - 222
  • [34] Peritonitis: Update on pathophysiology, clinical manifestations, and management
    Johnson, CC
    Baldessarre, J
    Levison, ME
    CLINICAL INFECTIOUS DISEASES, 1997, 24 (06) : 1035 - 1045
  • [35] Kawasaki Disease: Pathophysiology, Clinical Manifestations, and Management
    Dimitriades, Victoria R.
    Brown, Amanda G.
    Gedalia, Abraham
    CURRENT RHEUMATOLOGY REPORTS, 2014, 16 (06)
  • [36] Epidemiology, Clinical Manifestations, and Pathophysiology of Multisystem Inflammatory Syndrome in Children
    Rodriguez-Lozano, Ana Luisa
    del Carmen Toledo-Salinas, Carla
    Gutierrez, Beatriz Bayardo-
    Najera-Velazquez, Ruth Guadalupe
    ACTA PEDIATRICA DE MEXICO, 2023, 44 (03): : 221 - 241
  • [37] Epidemiology and resistance clinical impact of glycopeptide in Staphylococcus aureus
    Ruef, C
    INFECTION, 2004, 32 (06) : 315 - 327
  • [38] Kawasaki Disease: Pathophysiology, Clinical Manifestations, and Management
    Victoria R. Dimitriades
    Amanda G. Brown
    Abraham Gedalia
    Current Rheumatology Reports, 2014, 16
  • [39] Pituitary tumors: pathophysiology, clinical manifestations and management
    Arafah, BM
    Nasrallah, MP
    ENDOCRINE-RELATED CANCER, 2001, 8 (04) : 287 - 305
  • [40] Nosocomial infections caused by multiresistant bacteria. Clinical management of infections with multiresistant Staphylococcus aureus (MRSA)
    Knopf, HJ
    UROLOGE-AUSGABE A, 1997, 36 (03): : 248 - 254